Shell Asset Management Co. Sells 5,171 Shares of IQVIA Holdings Inc. $IQV

Shell Asset Management Co. lowered its stake in IQVIA Holdings Inc. (NYSE:IQV) by 55.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,085 shares of the medical research company’s stock after selling 5,171 shares during the quarter. Shell Asset Management Co.’s holdings in IQVIA were worth $776,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Artisan Partners Limited Partnership acquired a new stake in IQVIA in the second quarter valued at approximately $515,772,000. Norges Bank acquired a new position in shares of IQVIA during the second quarter worth $270,160,000. AQR Capital Management LLC lifted its stake in shares of IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after acquiring an additional 879,701 shares during the last quarter. Laurel Wealth Advisors LLC boosted its holdings in shares of IQVIA by 15,755.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock valued at $122,857,000 after acquiring an additional 774,681 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in IQVIA by 22.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock worth $492,659,000 after acquiring an additional 581,157 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Performance

NYSE:IQV opened at $166.70 on Tuesday. The company has a market capitalization of $28.39 billion, a PE ratio of 21.21, a P/E/G ratio of 1.61 and a beta of 1.37. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.70 and a current ratio of 0.75. The company has a 50 day simple moving average of $221.98 and a two-hundred day simple moving average of $209.06.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. During the same period in the prior year, the firm posted $3.12 EPS. The company’s quarterly revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

IQV has been the subject of several research reports. Stifel Nicolaus dropped their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research report on Friday, February 6th. BMO Capital Markets set a $250.00 price objective on IQVIA in a research note on Friday, February 6th. TD Cowen lifted their target price on shares of IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research report on Thursday, January 22nd. Robert W. Baird set a $258.00 target price on shares of IQVIA and gave the stock an “outperform” rating in a report on Wednesday, October 29th. Finally, Citigroup dropped their price target on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $238.20.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.